Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.
The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.
The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.
The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.
The conversation humorously suggests using immunosuppressants like ciclosporine and oral minoxidil for hair regrowth, with a satirical plan involving hair transplants from family members. It highlights the side effects and impracticality of such treatments, emphasizing the post's satirical nature.
People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
Using vitamin C in shampoo to adjust pH levels can improve hair health and reduce oiliness and dandruff. The user mixed vitamin C powder with conditioner, achieving positive results.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.
The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.
The conversation discusses using topical cetirizine for hair loss and questions its effectiveness and preparation. A user expresses interest in trying it if it can be dissolved in minoxidil.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
The conversation discusses using topical vitamin C in shampoo or serum for hair growth and thickness. The user mentions using the Nioxin system to maintain thick hair and is curious about the effects of vitamin C on hair growth.
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.